MINNEAPOLIS, MN / ACCESSWIRE / October 5, 2015 / PetVivo Holdings, Inc. (PINKSHEETS: PETV), an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices & therapeutics for pets, announced today that Mr. John Lai, Chief Executive Officer of PetVivo Holdings, will present at the 2015 Aegis Capital Growth Conference on Friday, October 9, 2015 at the The Encore at Wynn Las Vegas.
Mr. Lai will provide an overview and update of the Company's business and will be available to participate in one-on-one meetings with conference attendees.
Event: The 2015 Aegis Capital Growth Conference
Date: Friday, October 9, 2015
Time: 9:30 am (PDT)
Room: Brahms 2
Location: The Encore at Wynn Las Vegas
Address: 3131 S Las Vegas Blvd Las Vegas, Nevada 89109
The 3 day conference is expected to bring more than 100 presenting companies and more than 500 investors and others involved with the healthcare, technology, telecom and/or aerospace-defense sectors together for one-on-one meetings and various networking events.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (PINKSHEETS: PETV) is an emerging biomedical device company focused on the commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo's strategy is to acquire or in-license proprietary products from human medical device companies specifically for the companion animal market. The company's current pipeline includes seventeen animal and human therapeutics. An intellectual property portfolio of twenty patents protects the company's products, manufacturing processes and biomaterials. PetVivo's lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for commercial launch early next year.
For more information, visit: www.PetVivo.com
Forward-Looking Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.
Contact:
John Lai
Chief Executive Officer
PetVivo Holdings, Inc.
Email: info@petvivo.com
Phone: 612-296-7305
SOURCE: PetVivo Holdings, Inc.